FDA wants more data on promising ALS drug, frustrating patients seeking faster access

People living with amyotrophic lateral sclerosis, or ALS, in the U.S. will have to wait longer than their counterparts in Europe and Canada for access to a potentially beneficial treatment, even though the medicine is being developed here.

Patient advocates have responded by accusing the Food and Drug Administration of ignoring the desperate needs of people with ALS and reneging on commitments to speed the approval of new medicines to treat the fatal, neuro-degenerative disease.

Read the rest…

Read Original Article: FDA wants more data on promising ALS drug, frustrating patients seeking faster access »